Use of Campath [alemtuzumab] for induction and maintenance therapy in pancreas after kidney transplantation.
Phase of Trial: Phase IV
Latest Information Update: 15 Dec 2009
At a glance
- Drugs Alemtuzumab; Antithymocyte globulin; Mycophenolate mofetil; Tacrolimus
- Indications Kidney-pancreas transplant rejection
- Focus Therapeutic Use
- 15 Dec 2009 Actual number of patients (9) added as reported by ClinicalTrials.gov record.
- 25 Sep 2007 The expected completion date for this trial is now 1 Nov 2006.
- 10 Sep 2007 Status changed from in progress to discontinued.